Therapy with Interleukin-22 Alleviates Hepatic Injury and Hemostasis Dysregulation in Rat Model of Acute Liver Failure

Table 1

Effects of IL-22 therapy on the survival rate and liver function serobiomarkers of rats 48 h after D-GalN/LPS injection.

Groups	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	TBILI (mg/dL)	ALB (g/dL)	Mortality (%)
Control	105 ± 15.1	53.7 ± 8.9	211 ± 39.3	0.08 ± 0.01	4.4 ± 0.9	0
D-GalN/LPS	410 ± 45.8*	172 ± 31*	853 ± 214*	1.1 ± 0.02*	1.7 ± 0.3*	20*
D-GalN/LPS + IL-22	143 ± 23.3^#	62.6 ± 11.9^#	259 ± 41^#	0.1 ± 0.02^#	4.1 ± 0.7^#	0^#

Values are represented as mean ± SD. ^∗𝑃<0.05 versus control group; ^#𝑃<0.05 versus D-GalN/LPS group.